National Cancer Institute Basket/Umbrella Clinical Trials MATCH, LungMAP, and Beyond

被引：17

作者：

Chen, Alice P. ^{[1
]}

Eljanne, Mariam ^{[2
]}

Harris, Lyndsay ^{[3
]}

Malik, Shakuntala ^{[4
]}

Seibel, Nita L. ^{[4
]}

机构：

[1] NCI, Div Canc Treatment & Diag, Early Clin Trials Dev Program, Bethesda, MD 20892 USA

[2] NCI, Div Canc Biol, Bethesda, MD 20892 USA

[3] NCI, Canc Diag Program, Div Canc Res & Diag, Bethesda, MD 20892 USA

[4] NCI, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

来源：

CANCER JOURNAL | 2019年 / 25卷 / 04期

关键词：

ALCHEMIST; ALK; LungMAP; MPACT; NCI-MATCH; Pediatric MATCH; precision medicine; ANALYTICAL VALIDATION; MOLECULAR-ANALYSIS; BIOMARKERS; ASSAY;

D O I：

10.1097/PPO.0000000000000389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With advances in genetic testing and its common usage, the field of precision medicine has exploded in the field of oncology. The National Cancer Institute is uniquely positioned to lead in this area of research through its wide network of investigators, partnerships with pharmaceutical companies in drug development, and laboratory capabilities. It has developed a portfolio of trials as part of a Precision Medicine Initiative that uses various basket/umbrella designs to increase the understanding of treatment of cancer through genetic selection and targeted therapies. This article describes these trials, ALCHEMIST, LungMAP, NCI/NRG ALK Trial, MPACT, NCI-MATCH, and pediatric MATCH, and their contributions to the area of precision medicine.

引用

页码：272 / 281

页数：10

共 19 条

[11]

Heger M, 2012, TCGA LUNG CANC STUDY

[12] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations [J].

Hyman, David M. ;

Puzanov, Igor ;

Subbiah, Vivek ;

Faris, Jason E. ;

Chau, Ian ;

Blay, Jean-Yves ;

Wolf, Juergen ;

Raje, Noopur S. ;

Diamond, Eli L. ;

Hollebecque, Antoine ;

Gervais, Radj ;

Elena Elez-Fernandez, Maria ;

Italiano, Antoine ;

Hofheinz, Ralf-Dieter ;

Hidalgo, Manuel ;

Chan, Emily ;

Schuler, Martin ;

Lasserre, Susan Frances ;

Makrutzki, Martina ;

Sirzen, Florin ;

Veronese, Maria Luisa ;

Tabernero, Josep ;

Baselga, Jose .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) :726-736

[13] Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial [J].

Khoury, Joseph D. ;

Wang, Wei-Lien ;

Prieto, Victor G. ;

Medeiros, L. Jeffrey ;

Kalhor, Neda ;

Hameed, Meera ;

Broaddus, Russell ;

Hamilton, Stanley R. .

CLINICAL CANCER RESEARCH, 2018, 24 (03) :521-531

[14] Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial [J].

Lih, Chih-Jian ;

Harrington, Robin D. ;

Sims, David J. ;

Harper, Kneshay N. ;

Bouk, Courtney H. ;

Datta, Vivekananda ;

Yau, Jonathan ;

Singh, Rajesh R. ;

Routbort, Mark J. ;

Luthra, Rajyalakshmi ;

Patel, Keyur P. ;

Mantha, Geeta S. ;

Krishnamurthy, Savitri ;

Ronski, Karyn ;

Walther, Zenta ;

Finberg, Karin E. ;

Canosa, Sandra ;

Robinson, Hayley ;

Raymond, Amelia ;

Le, Long P. ;

Mcshane, Lisa M. ;

Polley, Eric C. ;

Conley, Barbara A. ;

Doroshow, James H. ;

Iafrate, A. John ;

Sklar, Jeffrey L. ;

Hamilton, Stanley R. ;

Williams, P. Mickey .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (02) :313-327

[15] Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial [J].

Lih, Chih-Jian ;

Sims, David J. ;

Harrington, Robin D. ;

Polley, Eric C. ;

Zhao, Yingdong ;

Mehaffey, Michele G. ;

Forbes, Thomas D. ;

Das, Biswajit ;

Walsh, William D. ;

Datta, Vivekananda ;

Harper, Kneshay N. ;

Bouk, Courtney H. ;

Rubinstein, Lawrence V. ;

Simon, Richard M. ;

Conley, Barbara A. ;

Chen, Alice P. ;

Kummar, Shivaani ;

Doroshow, James H. ;

Williams, Paul M. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (01) :51-67

[16] Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of "Master Protocols" in Lung Cancer [J].

Malik, Shakun M. ;

Pazdur, Richard ;

Abrams, Jeffrey S. ;

Socinski, Mark A. ;

Sause, William T. ;

Harpole, David H., Jr. ;

Welch, John J. ;

Korn, Edward L. ;

Ullmann, Claudio Dansky ;

Hirsch, Fred R. .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) :1443-1448

[17] US Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive [J].

Malik, Shakun M. ;

Maher, Virginia Ellen ;

Bijwaard, Karen E. ;

Becker, Robert L. ;

Zhang, Lijun ;

Tang, Shenghui W. ;

Song, Pengfei ;

Liu, Qi ;

Marathe, Anshu ;

Gehrke, Brenda ;

Helms, Whitney ;

Hanner, Diane ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2014, 20 (08) :2029-2034

[18]

Parsons D, 2019, ASCO ANN M JUN 2 CHI

[19] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

← 1 2 →